Citations Report
Clinical Schizophrenia & Related Psychoses : Citations & Metrics Report
Articles published in Clinical Schizophrenia & Related Psychoses have been cited by esteemed scholars and scientists all around the world. Clinical Schizophrenia & Related Psychoses has got h-index 41, which means every article in Clinical Schizophrenia & Related Psychoses has got 41 average citations.
Following are the list of articles that have cited the articles published in Clinical Schizophrenia & Related Psychoses.
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
Year wise published articles |
105 | 141 | 28 | 8 | 28 |
Year wise citations received |
543 | 553 | 590 | 563 | 587 |
| Journal total citations count | 6601 |
| Journal Impact Factor | 6.49 |
| Journal 5 years Impact Factor | 12.17 |
| Journal CiteScore | 11.19 |
| Journal h-index | 41 |
| Journal h-index since 2016 | 26 |
Normann, C. "NMDA-Rezeptor-Hypofunktion–der Schlüssel zur Pathophysiologie der Schizophrenie?." Die Psychiatrie 10, no. 03 (2013): 202-209. |
|
Normann, C. "NMDA-Rezeptor-Hypofunktion–der Schlüssel zur Pathophysiologie der Schizophrenie?." Die Psychiatrie 10, no. 03 (2013): 202-209. |
|
Normann, C. "NMDA-Rezeptor-Hypofunktion–der Schlüssel zur Pathophysiologie der Schizophrenie?." Die Psychiatrie 10, no. 03 (2013): 202-209. |
|
Normann, C. "NMDA-Rezeptor-Hypofunktion–der Schlüssel zur Pathophysiologie der Schizophrenie?." Die Psychiatrie 10, no. 03 (2013): 202-209. |
|
Kim, Min Kyung, Se Hyun Kim, Hyun Sook Yu, Hong Geun Park, Ung Gu Kang, Yong Min Ahn, and Yong Sik Kim. "The effect of clozapine on the AMPK-ACC-CPT1 pathway in the rat frontal cortex." International Journal of Neuropsychopharmacology 15, no. 7 (2012): 907-917. |
|
Sa??r, D., E. Kuruo?lu, M. E. Onger, and E. Yarar. "The Effects of folic acid and topiramate on peripheral nerve regeneration." Biotechnic & Histochemistry 95, no. 2 (2020): 105-112. |
|
Bugarski-Kirola, Dragana, Nakao Iwata, Snjezana Sameljak, Carol Reid, Thomas Blaettler, Laurie Millar, Tiago Reis Marques, George Garibaldi, and Shitij Kapur. "Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme." The Lancet Psychiatry 3, no. 12 (2016): 1115-1128. |
|
Singh, Asheesh, Parul Singh, and Chandra Kant Patel. "BENEFIT OF TOPIRAMATE IN THE TREATMENT OF SYMPTOMS OF BORDERLINE PERSONALITY DISORDER: A TYPICAL REVIEW." Journal of Drug Delivery and Therapeutics 7, no. 3 (2017): 1-7. |
|
SEPPÄLÄ, NIKO. "Clozapine: Clinical studies on adverse effects and interactions. Academic dissertation." PhD diss., University of Tampere, School of Medicine, 2014. |
|
Beck, K., R. McCutcheon, M. A. P. Bloomfield, F. Gaughran, T. Reis Marques, J. MacCabe, S. Selvaraj, David Taylor, and Oliver D. Howes. "The practical management of refractory schizophrenia–the Maudsley Treatment REview and Assessment Team service approach." Acta Psychiatrica Scandinavica 130, no. 6 (2014): 427-438. |
|
McCutcheon, Robert, Katherine Beck, Michael AP Bloomfield, Tiago R. Marques, Maria Rogdaki, and Oliver D. Howes. "Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms." Journal of Psychopharmacology 29, no. 8 (2015): 892-897. |
|
Kumari, Ranjana, and Sharma JVC Shyamala. "Stability indicating method development and validation of Topiramate using RP-HPLC in bulk and pharmaceutical dosage forms." Eur J Pharm Med Res 2, no. 7 (2015): 264-88. |
|
Ussher, Jane M., Janette Perz, Andrew Kellett, Suzanne Chambers, David Latini, Ian D. Davis, Duncan Rose, Gary W. Dowsett, and Scott Williams. "Health-related quality of life, psychological distress, and sexual changes following prostate cancer: A comparison of gay and bisexual men with heterosexual men." The journal of sexual medicine 13, no. 3 (2016): 425-434. |
|
Burt, Melissa. "Investigating the effect of prenatal immune activation, a risk factor for Schizophrenia, on hippocampal n-methyl-d-aspartate receptor function in a rodent model." (2013). |
|
Elkis, Helio, and Peter F. Buckley. "Treatment-resistant schizophrenia." Psychiatric Clinics 39, no. 2 (2016): 239-265. |
|
Fleischhacker, W. Wolfgang, Celso Arango, Paul Arteel, Thomas RE Barnes, William Carpenter, Ken Duckworth, Silvana Galderisi et al. "Schizophrenia—time to commit to policy change." Schizophrenia bulletin 40, no. Suppl_3 (2014): S165-S194. |
|
Meltzer, Herbert Y. "Refractory psychosis: treatment options and strategies." Psychiatric Times 31, no. 1 (2014): 34-34. |
|
Barnes, Thomas RE, and Carol Paton. "Antipsychotic polypharmacy in schizophrenia." CNS drugs 25, no. 5 (2011): 383-399. |
|
Onaolapo, A. Y., and O. J. Onaolapo. "Schizophrenia aetiology and drug therapy: A tale of progressive demystification and strides in management." Adv Pharmacol Pharm 6, no. 2 (2018): 19-42. |
|
Howes, Oliver D., Francis Vergunst, Siobhan Gee, Philip McGuire, Shitij Kapur, and David Taylor. "Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation." The British Journal of Psychiatry 201, no. 6 (2012): 481-485. |
|